Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...
GLP-1 agonists currently licensed for the treatment of obesity include a higher-dose version ... newer drug, Ozempic is more costly than Victoza. The current wholesale acquisition cost (WAC) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback